EAGAN, Minn., March 27, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5 in Washington, D.C. One poster was selected for the late-breaking session that highlights the newest and most exciting research.
Poster Presentations:
| Session Date & Time: | Monday, April 3, 8:00 AM - 12:00 PM Eastern Time | ||||||||||
| Topic Track: | Immunology | ||||||||||
| Session: | Adaptive Immunity to Cancer | ||||||||||
| Presentation Title: | A novel tumor vaccine platform: direct conjugation of antigens to the β-glucan PAMP Imprime PGG enhances antigen presentation and T cell priming | ||||||||||
| Session Location: | Poster Section 29 | ||||||||||
| Poster Board Number: | 22 | ||||||||||
| Abstract #: | 1703 | ||||||||||
| Session Date & Time: | Tuesday, April 4, 8:00 AM - 12:00 PM Eastern Time | ||
| Topic Track: | Immunology | ||
| Session: | Late-Breaking Research: Immunology | ||
| Presentation Title: | Imprime PGG modulates immunosuppressive myeloid components of the tumor microenvironment and drives enhanced antitumor efficacy in combination with checkpoint inhibitor therapies | ||
| Session Location: | Poster Section 35 | ||
| Poster Board Number: | 22 | ||
| Abstract #: | LB-199 |
| Session Date & Time: | Tuesday, April 4, 8:00 AM - 12:00 PM Eastern Time | ||
| Topic Track: | Immunology | ||
| Session: | Inflammation in the Tumor Microenvironment | ||
| Presentation Title: | Imprime PGG, a novel innate immune therapeutic in phase 2 clinical development, induces mobilization of monocytes and focalized recruitment of innate immune cells to tumor sites | ||
| Session Location: | Poster Section 28 | ||
| Poster Board Number: | 1 | ||
| Abstract #: | 3688 |
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA® in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.